Trial Information
Usage of Vinorelbin ORAL (Navelbine® ORAL) in the Treatment of Advanced Non-small Cell Lung Cancer(NSCLC)and Advanced Breast Cancer
Inclusion Criteria:
- At least 18 years old
- Male and female patients
- Advanced NSCLC (Stage III or IV) or Antracycline-resistant MBC
- Therapy with Navelbine capsules in any palliative treatment line
- Signed patient informed consent
Exclusion Criteria:
- Pregnancy and nursing
- All other exclusion criteria listed in SPC (summary of product characteristics)
- lack of signed Patient informed consent
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Progression-free-survival
Outcome Time Frame:
1 year after LPI
Safety Issue:
No
Authority:
Germany: Federal Institute for Drugs and Medical Devices
Study ID:
IOM-155
NCT ID:
NCT00890903
Start Date:
March 2009
Completion Date:
April 2012
Related Keywords:
- Non Small Cell Lung Carcinoma
- Metastatic Breast Cancer
- NSCLC
- non small cell lung carcinoma
- metastatic breast cancer
- MBC
- advanced breast cancer
- Navelbine
- Navelbine-ORAL
- Vinorelbine
- Vinorelbine-ORAL
- daily routine
- concomitant antiemetic therapy
- patient compliance
- germany
- non-interventional study
- oral anti cancer therapy
- quality of life
- Breast Neoplasms
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms